Skip to main content
Clinical Trials/NCT04242784
NCT04242784
Completed
Not Applicable

IMPlementation of Best PRactices fOr Acute Stroke Care - Developing and Optimizing Regional Systems of Stroke Care

Duke University9 sites in 1 country21,646 target enrollmentJanuary 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Stroke
Sponsor
Duke University
Enrollment
21646
Locations
9
Primary Endpoint
Change in Time from door to drug as measured by medical record
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this program is to develop a regional integrated stroke system that identifies, classifies, and treats patients with acute ischemic stroke more rapidly and effectively with reperfusion therapy.

Detailed Description

The design is based upon the implementation of best practice, that is, based on a comprehensive review of AHA guidelines regarding treatment of acute stroke, ICH (intracranial hemorrhage) and SAH(sub arachnoid hemorrhage). In the second phase, the project will be doing national and international surveys of best practices among comprehensive stroke centers and then combine evidence based guidelines and recommendation as well as expert consensus and guidelines when high level evidence is not available from the published literature. The aim to improve public stroke awareness, stroke symptom recognition within the time benefit window for treatment and calling 9-1-1, EMS transportation, and the proportion and speed of reperfusion therapy (fibrinolytic and in appropriate patients- endovascular treatment) in eligible patients. These improvements in acute stroke care delivery are expected to result in lower mortality, fewer recurrent strokes, and improved long term functional outcomes that we will measure.

Registry
clinicaltrials.gov
Start Date
January 1, 2019
End Date
April 30, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients \> 18 years of age who undergo the local acute code stroke process

Exclusion Criteria

  • In house patients with stroke are not included in this data set.

Outcomes

Primary Outcomes

Change in Time from door to drug as measured by medical record

Time Frame: From baseline (Q1, 2017), to Quarter 4 (2020)

The time frame starting from the earliest time that the patient is documented as arriving to the hospital to the beginning time of the administration of the drug (TPA)

Change in Time from Door to Tici 2c/3 flow measured by medical record

Time Frame: From baseline (Q1, 2017), to Quarter 4 (2020)

The time frame starting from the earliest time that the patient is documented as arriving to the hospital to the beginning time of Tici 2c/c flow noted in the vessel

Change in Time from Door to Administration of Reversal Agent as measured by medical record

Time Frame: From baseline (Q1, 2017), to Quarter 4 (2020)

The time frame starting from the earliest time that the patient is documented as arriving to the hospital to the beginning time of the administration of the drug (reversal agent)

Secondary Outcomes

  • Change in Number of Deaths from Stroke as measure by medical record(From baseline (Q1, 2017) to Quarter 4 (2020))
  • Change in Functional Long Term Outcomes as measured by Modified Rankin Scale(From baseline , 3 months)

Study Sites (9)

Loading locations...

Similar Trials